1. Home
  2. |Insights
  3. |COVID-19 Benchmarking Survey Results

COVID-19 Benchmarking Survey Results

Client Alert | less than 1 min read | 03.18.20

As part of our continuing commitment to help our clients address the effects of COVID-19, we are providing the initial, anonymized, and aggregated results from our benchmarking questionnaire.  We continue to gather information and update the responses, but given the rapidly changing environment, we wanted you to have this information sooner than later. 

Our teams are working around the clock to address these and other impacts.  Please reach out if you need assistance, and above all else, our best wishes for your continued good health.

Contacts

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...